Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

February 29, 2024

https://www.prnewswire.com/news-releases/immunic-presents-data-from-phase-2-calliper-and-calvid-1-trials-of-vidofludimus-calcium-at-the-actrims-forum-2024-302073978.html

NEW YORK, Feb. 29, 2024 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of data from the company’s phase 2 CALLIPER and CALVID-1 clinical trials of lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in two poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024, taking place from February 29 to March 2, in West Palm Beach, FL.

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.